^
BIOMARKER:

CD22 positive

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Entrez ID:
Related biomarkers:
17d
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. (PubMed, J Clin Oncol)
InO is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL. SOS after hematopoietic stem-cell transplantation and prolonged cytopenias were notable. CD22 modulation was identified as a mechanism of resistance. Expanded study of InO combined with chemotherapy is underway.
Clinical • P2 data • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
19d
Haploidentical Donor-Derived CAR-T Cells Can be Safely and Effectively Co-Infused with the Haploidentical Graft, Depleted of Αβ T Cells: Report of Case Series (TCT-ASTCT-CIBMTR 2022)
Three patients had relapsed BCP-ALL after both haploidentical HSCT and autologous CD19 CAR-T cell, 3 after haploidentical HSCT, 2 after autologous CD19 CAR-T cell, 3 after intensive chemotherapy +/- blinatumomab (n=2)...Five (45%) pts received treosulfan-based regimen, while TBI-based regimen was used in 6 (55%) pts. GvHD prophylaxis included tocilizumab and abatacept...The infusions did not compromise engraftment and GVHD control, while specific CAR-T toxicity was mild and manageable. We have documented allogeneic haploidentical CAR-T expansion and persistence.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Ovastat (treosulfan) • Actemra IV (tocilizumab) • Orencia (abatacept)
22d
ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (clinicaltrials.gov)
P1, N=36, Recruiting, University of Virginia | Trial completion date: Nov 2025 --> Nov 2024 | Trial primary completion date: Jan 2022 --> Jan 2023
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cytarabine • prednisone • vincristine • methotrexate • Besponsa (inotuzumab ozogamicin) • daunorubicin • Oncaspar liquid (pegaspargase) • Otrexup (methotrexate)
2ms
Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain (ASH 2021)
Figure 1. Overall survival according to ALL status at inotuzumab start (A) and to duration of first complete remission (B)
Clinical
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
3ms
Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease (ASH 2021)
Prior to InO, blinatumomab was administered in n=14 and local irradiation in n=5 pts...Sinusoidal obstruction syndrome (SOS) was reported in 1 patient after transplant; conditioning in this patient consisted of treosulfan/fludarabine/thiotepa... This outcome analysis demonstrates that treatment with InO is an effective and promising approach in r/r-ALL patients with EM disease. However, allo-SCT alone seems not to be effective in maintaining disease control. Thus, autologous chimeric antigen receptor T-cells or advanced bi-specific antibodies as consolidation therapy should be evaluated in the future.
Clinical
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV • Ovastat (treosulfan) • thiotepa
3ms
Haploidentical Donor-Derived CAR-T Cells Are Safely and Effectively Co-Infused with the Haploidentical Graft, Depleted of Ab T Cells: Report of Case Series (ASH 2021)
Three patients had relapsed BCP-ALL after both haploidentical HSCT and autologous CD19 CAR-T cell, 3 after haploidentical HSCT, 2 after autologous CD19 CAR-T cell, 3 after intensive chemotherapy +/- blinatumomab (n=2)...Five (45%) pts received treosulfan-based myeloablative preparative regimen, while TBI-based regimen was used in 6 (55%) pts. GvHD prophylaxis included tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on day -1, +7, +14, +28...We have documented allogeneic haploidentical CAR-T expansion and persistence. Prospective testing of the approach is warranted.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CD34 (CD34 molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Ovastat (treosulfan) • Actemra IV (tocilizumab) • Orencia (abatacept)
3ms
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=1, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=28 --> 1 | Trial completion date: May 2023 --> May 2021 | Recruiting --> Terminated; Suitable patients were not recruited
Clinical • Enrollment change • Trial completion date • Trial termination
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD20 negative • CD22 positive
|
LB1909
3ms
Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
P1, N=26, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
4ms
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV
4ms
TZR gene therapy for CD22-positive B-cell neoplasias (DGHO 2021)
Having demonstrated the efficacy and safety of the lead CD22 TCR candidate, we now will analyze efficiency in a xenograft model and on material of patients that relapsed after a CD19 CAR T cell therapy and of acute lymphoblastic leukemia (ALL) -relapsed children after treatment with the CD22 targeting agent inotuzumab. Patients that have relapsed from CD19 or CD22 CAR therapy might be rescued by the treatment with CD22 TCR T cells. We here demonstrate the development of a CD22 candidate TCR for further preclinical development and translation into early clinical trials in patients with CD22-positive B cell malignanices.
IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
5ms
Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
P1, N=26, Not yet recruiting, Dana-Farber Cancer Institute
New P1 trial • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
5ms
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. (PubMed, Leuk Lymphoma)
This drug combination is not possible within a therapeutically useful range of doses due to toxicities. Antitumor activity was observed in heavily pretreated patients (ClinicalTrials.gov, Identifier NCT01535989).
Clinical • P1 data • Journal • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Torisel (temsirolimus) • Besponsa (inotuzumab ozogamicin)
6ms
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Active, not recruiting --> Recruiting | Initiation date: Jan 2021 --> May 2021
Clinical • Enrollment open • Trial initiation date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 expression • CD22 positive
7ms
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Nov 2021
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
7ms
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients (clinicaltrials.gov)
P4, N=102, Recruiting, Pfizer | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Nov 2022
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
7ms
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1b/2, N=42, Recruiting, Roswell Park Cancer Institute | Trial completion date: Feb 2023 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2023
Clinical • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
8ms
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
P1, N=12, Recruiting, Hebei Yanda Ludaopei Hospital | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
YT-19/22
9ms
[VIRTUAL] A Novel CD22-CAR against B-cell malignancies (CIMT 2021)
We then performed a set of experiments and observed that while IS7- CAR killed less rapidly than m971-CAR in vitro, it was as efficient in controlling lymphoma xenograft models in vivo. Thus, IS7-CAR is a potential alternative candidate for treatment of refractory B-cell malignancies.
IO biomarker
|
CD22 (CD22 Molecule)
|
CD19 expression • CD22 positive
9ms
Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. (PubMed, Cancer Biother Radiopharm)
BAY 1862864 was safe and tolerated in patients with R/R-NHL. The Clinical Trial Registration numbers: NCT02581878 and EudraCT 2014-004140-36.
P1 data • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
epratuzumab-thorium-227 (BAY1862864)
9ms
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Dec 2020 --> Jun 2021
Clinical • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
fludarabine IV
11ms
Clinical • New P1/2 trial
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
11ms
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 expression • CD22 positive
11ms
Clinical • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
11ms
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22. (PubMed, Clin Cancer Res)
InO demonstrated a favorable benefit-risk profile versus SC in patients with higher and lower CD22 expression. Patients with high CD22 expression and normal cytogenetics benefited the most from InO therapy.
Clinical • PK/PD data • Journal
|
CD22 (CD22 Molecule)
|
CD22 overexpression • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
12ms
[VIRTUAL] Circulating CD19-Negative CD22-Positive Progenitor Population: A Diagnostic Pitfall for Minimal Residual Disease Detection in B-Lymphoblastic Leukemia Post CD19-Targeted Immunotherapy (USCAP 2021)
Circulating CD19-negative CD22-positive precursors are commonly detected at low levels in peripheral blood samples, they should be distinguished from B-ALL MRD especially in the setting of CD19-targeted therapy.
Clinical • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD24 (CD24 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MME (Membrane metallo-endopeptidase)
|
CD22 positive
12ms
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies (clinicaltrials.gov)
P1/2, N=20, Recruiting, Affiliated Hospital to Academy of Military Medical Sciences | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2019 --> Aug 2021
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
12ms
Clinical • New P1/2 trial
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
1year
Clinical • Enrollment open
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
1year
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
Clinical • Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
1year
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD22 positive
1year
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD22 positive
1year
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1/2, N=44, Suspended, Leland Metheny | Recruiting --> Suspended
Trial suspension
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
Clinical • Trial primary completion date
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
LB1909
1year
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 expression • CD22 positive
1year
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
|
CD19 expression • CD22 positive
1year
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial primary completion date: Dec 2020 --> Apr 2021 | Suspended --> Recruiting
Enrollment open • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
over1year
CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Hebei Yanda Ludaopei Hospital
Clinical • New P1 trial
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
YT-19/22
over1year
Clinical • Enrollment open
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
2years
Clinical • Trial completion
|
CD22 (CD22 Molecule)
|
CD22 positive
|
epratuzumab-thorium-227 (BAY1862864)
almost3years
Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=21, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | N=60 --> 21 | Trial completion date: Oct 2020 --> Dec 2019 | Trial primary completion date: Mar 2020 --> Apr 2019
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
epratuzumab-thorium-227 (BAY1862864)
almost3years
Clinical • Trial completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
epratuzumab-thorium-227 (BAY1862864)